Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years
The iwCLL 2017 meeting
T-SPOT assay for tuberculosis and cytomegalovirus - benefits, results and next steps
How can we assess quality of life in AML patients?
Predict response to immune checkpoint inhibition in acute myeloid leukemia (AML) using biomarkers
Naval G. Daver